Private Equity Dermatology: Top Firms in 2026

Key Facts

• More than 35 PE-backed dermatology platforms operate across nearly 20 states as of 2024, with approximately 85 practice acquisitions completed in 2023 alone.
• The US dermatology market is valued at $7.7 to $8.4 billion and is projected to reach $8.6 billion by 2026, growing at a blended rate of 6.5% annually.
• Texas and Florida together accounted for 36% of PE-acquired clinic locations through 2018 and remain the two largest state markets by clinic concentration.
• The dominant investment strategy is platform acquisition followed by systematic bolt-on acquisitions, with secondary and tertiary buyouts accelerating since 2022.
• The eight largest PE-backed platforms have disclosed a combined $1.4 billion-plus in funding, led by Forefront Dermatology at $570 million and Advanced Dermatology and Cosmetic Surgery at $463.7 million.
• Only 10% to 15% of private dermatology practices are PE-owned, leaving substantial runway for further consolidation.
• A "consolidation of consolidators" phase is underway, with three major platform-to-platform mergers closing in 2022 alone.

Dermatology Market Overview

Dermatology private equity has grown into one of healthcare's most active investment categories, with the US dermatology market generating $7.7 to $8.4 billion in annual revenue. Medical dermatology grows at approximately 4.0% per year. Cosmetic dermatology grows at 8.5%, driven by post-COVID demand, rising disposable income, and social media normalization of aesthetic procedures.

Several structural factors make dermatology one of the most defensible niches in healthcare PE. The US population aged over 70 will grow from 38 million in 2020 to 53 million by 2030. Skin cancer is the most common cancer in the US, with roughly 9,500 Americans diagnosed daily and annual treatment costs exceeding $8.1 billion.

Supply constraints reinforce the investment thesis. Of the 11,865 active dermatologists in patient care, 44.8% are over age 55 and nearing retirement. Accredited residency programs graduate only 530 dermatologists per year. That net shortfall pushes independent practices toward PE-backed platforms offering recruitment infrastructure and administrative scale. Average wait times in major metropolitan markets run 35.4 days, a gap that motivates practice consolidation.

Texas and Florida were the earliest high-concentration markets, accounting for 36% of PE-acquired clinic locations through 2018. Florida led in the initial years; Texas accelerated from 2016 onward. The Southwest is anchored by Platinum Dermatology Partners, while the Midwest is historically dominated by Forefront Dermatology and DOCS Dermatology.

QualDerm Partners, formed from a 2022 merger with Pinnacle Dermatology, now spans 17 states with 158 practices. The New York metro market features two distinct PE-backed operators: Schweiger Dermatology Group and The Dermatology Specialists, each pursuing different capital structures.

Dermatology Private Equity: Firm Comparison

Because sponsor-level assets under management are largely undisclosed in this sector, the table below uses platform-level disclosed funding as the best available proxy for capital scale.

Forefront leads on platform funding at $570 million. ADCS holds the largest single clinic footprint at 193 locations. QualDerm's post-merger scale of 158 practices across 17 states gives it the widest geographic breadth among active platforms.

Top Picks by Investment Strategy

Largest Platform Footprint: Advanced Dermatology and Cosmetic Surgery, backed by Audax Private Equity and Harvest Partners, with 193 clinics across 14 states and 47 documented practice acquisitions between 2012 and 2017.

Multi-State Scale Leader: QualDerm Partners, backed by Cressey and Company and Granite Growth Health Partners, operating 158 practices in 17 states after absorbing Pinnacle Dermatology in a 2022 platform merger.

Recapitalization Track Record: Forefront Dermatology demonstrates the multi-bite model at its most mature, completing three consecutive sponsor transitions: Varsity Healthcare Partners to OMERS Private Equity in 2016, then to Partners Group in 2022, growing from 37 clinics to 121 along the way.

Southwest Consolidator: Platinum Dermatology Partners, backed by Sterling Partners, assembled 100 clinic locations and 170 physicians through its 2022 merger with West Dermatology, creating the dominant Southwest footprint spanning Arizona, Texas, California, and Nevada.

NYC Market Leader: Schweiger Dermatology Group, backed by LNK Partners and LLR Partners, operates the highest-density urban dermatology network with 40-plus clinics across New York, New Jersey, and Midwest locations added via the January 2024 acquisition of United Skin Specialists.

Growth Equity Rising Star: The Dermatology Specialists operates 30-plus locations across five New York City boroughs. GarMark Partners provided mezzanine financing in May 2023. It is one of the few physician-founded platforms taking structured growth capital rather than a full leveraged buyout.

Medical Aesthetics Specialist: Skin Spirit, backed by KKR, operates as a standalone medical aesthetics and med spa platform. Its backing by one of the world's largest PE firms signals that the aesthetics-adjacent thesis within dermatology has reached institutional scale.

Top Dermatology PE Platforms in Detail

Advanced Dermatology and Cosmetic Surgery (ADCS)

ADCS is the most prolific acquirer by clinic count, with 193 locations across 14 states and $463.7 million in disclosed platform funding. Audax Private Equity made the initial platform acquisition in 2012, taking on 53 clinics. That deal launched one of the first major PE dermatology investments on record. The subsequent add-on campaign produced 47 additional practice acquisitions and 92 new clinics between 2012 and 2017. Harvest Partners later joined as a co-sponsor in a secondary transaction.

The platform covers Arizona, Colorado, Florida, Georgia, Maryland, Michigan, Nevada, Ohio, Pennsylvania, Rhode Island, South Carolina, Texas, Virginia, and Wyoming. That 14-state footprint makes ADCS the nearest approximation to a true national network among currently active platforms.

Forefront Dermatology

Forefront is the defining proof of concept for the multi-bite recapitalization model in dermatology. Varsity Healthcare Partners made the original investment in 2014, with the platform operating 37 clinics and 42 dermatologists in three states. OMERS Private Equity acquired the platform in 2016, by which point Forefront had reached 82 clinics and 90 dermatologists across 11 states. That transaction marked the first major secondary buyout in dermatology PE.

Partners Group completed the third bite in 2022, acquiring a platform with 121 clinics and $570 million in total disclosed funding. Physicians who rolled equity through each transaction received three consecutive valuation step-ups as the network expanded from a regional Wisconsin base to a 15-state presence.

QualDerm Partners

QualDerm Partners is the clearest execution of the consolidation-of-consolidators thesis. Backed by Cressey and Company and Granite Growth Health Partners, it absorbed Pinnacle Dermatology in a 2022 merger that produced 158 practices across 17 states. Chicago Pacific Founders had previously backed Pinnacle before the combination.

The combined entity rebranded as "A Skin and Aesthetics Wellness Family," expanding beyond medical dermatology into cosmetic services and aesthetics. For institutional investors evaluating the broadest US market exposure in this sector, QualDerm's geographic diversity across the Carolinas, Ohio, Tennessee, Virginia, Indiana, and Michigan makes it the most widely distributed active platform.

US Dermatology Partners

US Dermatology Partners anchors South-Central and Mid-Atlantic dermatology PE with $399.2 million in disclosed funding and 65 clinics. The platform spans Texas, Arizona, Maryland, Missouri, Oklahoma, Louisiana, Kansas, and Virginia. Multiple general partners have backed it across successive transactions, including ABRY Partners, Providence Equity, and Candescent Partners.

That multi-sponsor history reflects robust secondary market demand for the asset. The practice covers medical, surgical, and cosmetic dermatology in markets where skin cancer volume and cash-pay cosmetic demand both run high. The result is a resilient payer mix across insurance reimbursement and out-of-pocket revenue streams.

Schweiger Dermatology Group

Schweiger holds the most defensible urban position in US dermatology PE. Backed by LNK Partners, LLR Partners, and SV Health Investors, the platform disclosed $175.4 million in funding and operates 40-plus clinics concentrated in the New York and New Jersey metro areas. The January 2024 acquisition of United Skin Specialists added 10 Midwest offices across Illinois, Minnesota, and Missouri.

That expansion marks a deliberate diversification beyond the core NYC market. Its track record in commercial payer negotiations and high patient throughput sets a clear benchmark for urban market operators seeking a PE partner with proven regional scale.

Epiphany Dermatology

Epiphany's 2022 recapitalization from CI Capital Partners to Leonard Green and Partners demonstrates how established mid-market dermatology platforms attract marquee buyout sponsors in secondary transactions. Based in Austin, Texas, the platform operates 36-plus clinics across Arizona, Iowa, Missouri, New Mexico, Oklahoma, and Texas. Epiphany focuses on medical dermatology in South Central and Mountain West markets where the dermatologist shortage is most acute.

Under CI Capital, Epiphany completed nine practice acquisitions and opened 19 new clinics in its first two years. Leonard Green brings institutional operating infrastructure to a platform that investors now view as a scaled, investment-grade asset ready for further consolidation.

Anne Arundel Dermatology

Anne Arundel Dermatology built 43 clinics across Maryland, Tennessee, and Virginia with $94.2 million in disclosed funding. New Mountain Capital and Pantheon Ventures back the platform. Between 2015 and 2018, it completed 12 practice acquisitions generating 20 new clinics, establishing one of the most consistent mid-paced acquisition records in the Mid-Atlantic corridor.

New Mountain Capital's healthcare services focus brings operational expertise in revenue cycle management and payer contract optimization. Pantheon Ventures adds co-investment scale for add-on financing. For practice owners in the Virginia-Maryland-Tennessee corridor, Anne Arundel's regional density and proven acquisition pace make it the natural fit among PE-backed buyers.

Aqua Dermatology

Aqua Dermatology emerged from the 2022 merger of Waters Edge Dermatology and Riverchase Dermatology, combining two Florida-anchored platforms into the leading Southeast regional consolidator. Gryphon Investors backs the combined entity, which operates 37-plus clinics across Florida and Georgia. Riverchase had navigated two prior ownership transitions under GTCR and Prairie Capital before the Gryphon-led merger, demonstrating resilience across multiple capital structures.

Florida's population growth and high concentration of sun-exposure-related skin cancer diagnoses create durable demand tailwinds for any platform with concentrated regional coverage.

Investment Trends Shaping Dermatology PE

Consolidation of Consolidators

The market has moved past acquiring individual independent practices. Three platform-to-platform mergers closed in 2022: QualDerm absorbed Pinnacle (158 practices, 17 states); Platinum merged with West Dermatology (100 locations, 170 physicians); and Waters Edge combined with Riverchase to form Aqua Dermatology.

General partners from the early dermatology fund cohort are reaching the end of their 10-year fund cycles. That timing accelerates secondary buyouts and platform mergers as the primary exit mechanism. Analysts project consolidation from 35-plus active platforms to 10 to 15 dominant national consolidators within the next several years.

Med Spa and Medical Aesthetics Integration

The 10,000-plus US med spa locations generate an average of $1.4 million in annual revenue. This adjacent market is a primary growth target for dermatology PE platforms. PE-backed dermatology practices already perform 40% of their procedure volume in cosmetic services, compared to 20% at independent practices.

KKR's investment in Skin Spirit signals that global buyout firms now treat medical aesthetics as a standalone investment thesis. ACE and Company's backing of MedSpa Partners reinforces that view. QualDerm's rebrand to "A Skin and Aesthetics Wellness Family" reflects the same strategic logic from within the traditional dermatology PE category.

Growth Equity Structures Expanding the Funnel

PE deal flow in dermatology shifted toward growth-equity-style structures in 2023. GarMark Partners' mezzanine financing of The Dermatology Specialists and a credit-focused PE investor's structured debt commitment to Integrated Dermatology both use equity participation rather than controlling leveraged buyouts. These structures appeal to physician-owned groups that want operational support and capital access without surrendering majority board control.

As the pool of practices willing to accept full buyouts shrinks, growth equity and mezzanine structures extend the available investment opportunity set for fund managers seeking to deploy dry powder.

Regulatory and Antitrust Headwinds

The FTC, DOJ, and HHS launched a joint inquiry into PE consolidation in healthcare in 2024, introducing compliance cost and deal-timeline risk for the largest dermatology platforms. The corporate practice of medicine (CPOM) doctrine restricts direct corporate ownership of medical practices and varies by state. It requires all PE-backed platforms to operate through a management services organization (MSO) structure.

The MSO owns non-clinical operations, while the physician retains the medical practice entity. This arrangement allows PE investors to capture operational economics across multi-site networks while remaining compliant with CPOM restrictions.

Teledermatology and Operational Technology

PE-backed platforms operating 40-plus clinics can justify investments in centralized electronic health records, AI-assisted diagnostic workflows, and digital dermatopathology reading that solo practices cannot fund independently. Teledermatology extends physician reach into underserved markets without requiring new physical clinic locations. Revenue cycle management centralization is the most consistently cited value-creation lever in dermatology PE.

Large platforms renegotiate payer contracts at scale and invest in billing compliance programs that reduce Medicare audit risk from over-coding.

How to Evaluate Dermatology PE Firms

The most important due diligence variable for a physician considering a first PE sale is the sponsor's fund cycle stage. A fund within two years of its 10-year end faces exit pressure that may compress the hold period. That compression can force a secondary sale before the platform reaches optimal scale for physician equity holders.

Clinical autonomy provisions deserve explicit contractual language, not verbal assurances. Governance structure should specify board composition, the ratio of physician to investor board seats, and physician control over work schedules, provider recruitment, and clinical protocols. The 65% of dermatology residents who report unwillingness to work for PE-backed practices demonstrates that platforms with physician-led governance attract stronger recruitment pipelines. This is a real operating KPI, not just a qualitative concern.

Track record is the most objective differentiator across platforms. Request the number of practices acquired under the current sponsor, physician attrition rates, and net clinic count growth since the initial investment. For institutional investors evaluating PE funds with dermatology holdings, platform-level disclosed funding totals and documented acquisition pace provide useful comparables in the absence of public financial statements.

Rollover equity mechanics require close analysis. Dermatology PE transactions typically require selling physicians to reinvest 10% to 40% of proceeds into equity in the combined entity. The lockup period and valuation basis for that equity determine whether the second bite will be as attractive as the initial liquidity event. Physicians who negotiate rollover terms aligned to their income timeline will capture more upside from the next recapitalization.

Which Firm Fits Your Needs?

Practice owners in Texas, Florida, or Arizona with multi-location operations are best positioned to run a competitive marketing process with the national consolidators. ADCS, QualDerm, and US Dermatology Partners are all actively expanding in those geographies and have multi-state integration track records. A formal competitive process consistently produces better economic outcomes in dermatology healthcare M&A because multiple active acquirers compete for the same deal flow.

Physicians in the New York metro area or Midwest seeking a regional operator rather than a national platform should evaluate Schweiger Dermatology Group first. Its urban market density and 2024 Midwest expansion set it apart from the larger national players. Solo practitioners in Florida or Georgia looking for a regionally focused buyer will find Aqua Dermatology the most relevant acquirer. Mid-Atlantic practice owners in Maryland or Virginia have a natural geographic fit with Anne Arundel Dermatology.

Institutional investors building diversified healthcare PE allocations should differentiate between sponsors at different fund cycle stages. Partners Group, Leonard Green and Partners, New Mountain Capital, and Gryphon Investors all hold active dermatology portfolio companies as of 2024. For LPs seeking a cosmetic-adjacent return profile alongside core dermatology PE exposure, KKR's Skin Spirit and ACE and Company's MedSpa Partners represent the medical aesthetics thesis as a distinct allocation.

Methodology

This guide to private equity in dermatology covers platforms and sponsors active from 2012 through early 2026. Platform statistics and disclosed funding data draw from a 2019 peer-reviewed dermatology journal study of PE-backed dermatology groups, a 2024 physician advisory white paper, and a 2024 healthcare consulting firm analysis of the dermatology market. Market size figures reference IBISWorld US dermatology industry data as cited in academic literature. Demographic and skin cancer data sourced from the American Cancer Society, the US Census Bureau, and the American Academy of Dermatology. Sponsor-level AUM is largely undisclosed in this sector; the comparison table uses platform-level disclosed funding as the best available proxy. Firms are included based on documented PE sponsorship, confirmed transaction history, or publicly available platform scale data.